InflaRx N.V.

As of June 30, 2026, InflaRx N.V. carries a market capitalization of 292.67M, placing it among publicly traded companies globally. Its enterprise value stands at 134.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

InflaRx N.V.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, InflaRx N.V. has 147.37M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is -16,220.51, and the price-to-book ratio stands at 2.00.

As of June 30, 2026, InflaRx N.V. maintains a current ratio of 8.22, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.57, indicating moderate leverage, while an interest coverage ratio of -591.44 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, InflaRx N.V. posted a negative return on equity (ROE) of -38.52, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -32.57, reflecting losses generated across the asset base. The company generates approximately -150.20 in revenue per employee across its workforce of 67.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, InflaRx N.V. recorded 12,282.00 in income tax expense. The company reported a pretax loss of -39.08M and -39.14M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, InflaRx N.V.'s stock has gained approximately 29.42% over the past 52 weeks. The 50-day moving average sits at 1.68, while the 200-day moving average is 1.42.

Over the twelve months ended June 30, 2026, InflaRx N.V. generated -10,101.00 in revenue and converted that into -39.14M in net income, yielding earnings per share of -0.47. EBITDA reached -36.23M, while operating income came in at -36.54M.

As of June 30, 2026, InflaRx N.V. holds 158.51M in cash and equivalents against 833,179.00 in total debt, resulting in a net debt position of -146.57M. Total book value stands at 146.18M, with working capital of 145.27M providing operational flexibility.

InflaRx N.V. produced -23.71M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -135,940.00 in capital expenditures, free cash flow totaled -23.85M - equivalent to -0.29 per share.

Over the twelve months ended June 30, 2026, InflaRx N.V. posted a gross margin of 48,201.61, reflecting its pricing power and cost economics. The operating margin of 361,793.12 and net profit margin of 387,532.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.55: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -42.92, meaning InflaRx N.V. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, InflaRx N.V. has an Altman Z-Score of 5.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.